7.9. treatment failure intravesical therapy. 7.9.1. recurrence intravesical chemotherapy patients nmibc recurrence chemotherapy regimen benefit bcg instillations. prior intravesical chemotherapy impact effect bcg instillations . 7.9.2. treatment failure intravesical bcg immunotherapy several categories bcg failures, broadly defined hg disease occurring bcg therapy, proposed (see table 7.2). non-muscle-invasive bc may respond (bcg refractory) may relapse initial response (bcg relapsing). evidence suggests patients bcg relapse better outcomes bcg refractory patients . able specify subgroup patients additional bcg unlikely provide benefit, category bcg-unresponsive tumour defined. bcg instillations patients associated increased risk progression . category bcg-unresponsive tumours comprises bcg-refractory bcg-relapsing tumours (see table 7.2) . definition developed consultation u.s. food drug administration (fda), particular promote single-arm trials provide primary evidence effectiveness setting . patients experience recurrence high-grade nmibc bcg without meeting bcg-unresponsive criteria may benefit additional bcg therapy. category high risk patients lies bcg-naïve bcg-unresponsive nmibc termed bcg-exposed , includes: bcg-resistant: persistent recurrent ta hg and/or cis disease three months following least five six doses induction bcg. according definition adequate bcg (table 7.2), patients received inadequate bcg.delayed relapse inadequate bcg: indicate ta/t1 hg cis patients found disease free three-months evaluation recur 6 24 months without receiving induction course.delayed relapse adequate bcg: indicate patients disease free adequate bcg, subsequently experience high-grade recurrence outside bcg-unresponsive window (>6 mo ta/t1 >12 mo cis), 24 months. non-hg recurrence bcg considered bcg failure. table 7.2: categories high-grade recurrence bcg whenever mibc detected follow-up.bcg-refractory tumour1. t1 hg/g3 tumour present 3 months .2. ta hg/g3 tumour present 3 months and/or 6 months, either re-induction first course maintenance .3. cis (without concomitant papillary tumour) present 3 months persists 6 months either re-induction first course maintenance. patients cis present 3 months, additional bcg course achieve complete response > 50% cases .4. hg tumour appears bcg maintenance therapy*.bcg-relapsing tumourrecurrence hg/g3) tumour completion bcg maintenance, despite initial response .bcg-unresponsive tumourbcg-unresponsive tumours include bcg refractory tumours develop t1/ta hg recurrence within 6 months completion adequate bcg exposure** develop cis within 12 months completion adequate bcg exposure .bcg-exposed tumour 1. ta hg/g3 cis present three months evaluation induction bcg only2. delayed relapse adequate inadequate bcgbcg intolerancesevere side effects prevent bcg instillation completing treatment . * patients lg recurrence bcg treatment considered bcg failure.** adequate bcg defined completion least 5 6 doses initial induction course plus atleast 2 6 doses second induction course 2 3 doses maintenance therapy. 7.9.3. treatment bcg-unresponsive tumours, bcg-exposed tumours, bcg relapses lg recurrences bcg treatment patients bcg-unresponsive disease unlikely respond bcg therapy; rc therefore standard preferred option. currently, several bladder preservation strategies investigated cytotoxic intravesical therapies [402-405], device assisted instillations [406-408], intravesical immunotherapy , combination therapies (mainly sequential chemotherapies see section 7.4.4.3), systemic immunotherapy gene therapy [412-414]. phase iii rct including predominantly high-risk nmibc patients failing least previous induction course bcg, mmc combined microwave-induced hyperthermia provided 35% overall dfs 2 years compared 41% control arm (treated either bcg, mmc mmc electromotive drug administration discretion investigator). pre-planned sub-analysis, mmc microwave- induced thermotherapy showed lower response rates cis recurrences higher dfs non-cis papillary tumours (53% vs. 24%) . promising data bcg-unresponsive cohorts patients cis alone concomitant papillary tumours recently reported following new immunotherapies. systemic pembrolizumab achieved 40% complete response rate prospective phase ii study maintained 48% patients 12 months (n = 101), resulting fda approval study drug patient population . promising data phase iii multicentre rct intravesical nadofaragene firadenovec showed complete response 53.4% patients bcg-unresponsive cis maintained 45% one year initially responded . secondary analysis indicates combination post- treatment titres serum anti–human adenovirus type-5 antibody fold change baseline predict treatment efficacy . additional ongoing studies addressing combination intravesical systemic immunotherapy . systematic review meta-analysis including 4 rcts 24 single-arm studies (all currently available prospective studies) assessed bladder-sparing treatments following bcg failure . significant heterogeneity trial designs patient characteristics included studies, different definitions bcg failures used, missing information prior bcg courses may account variability efficacy different compounds assessed across different trials. higher number previous bcg courses, bcg refractory/unresponsive cis predicted lower response rates. pooled 12-month response rates 24% trials > 2 prior bcg courses 36% > 1 bcg courses. initial response rate predict durable responses highlighting need longer-term follow-up. recently, systematic review assessing 42 prospective trials bladder-preserving treatments bcg showed patients papillary-only recurrences appeared effectively treated (median recurrence free rate 44% 1 year, median progression-free rate 89% median follow-up 19 months) cis-containing tumours (median complete response rate 17% 1 year median progression-free rate 95% median follow-up 12 months), highlighting potential biological differences two tumour entities analysed separately reporting results clinical trials . present time, treatments rc considered oncologically inferior patients bcg- unresponsive disease . various studies suggest repeat-bcg therapy appropriate non-hg even hg recurrent tumours; namely relapsing beyond one year bcg exposure (cases meet criteria bcg-unresponsive disease) . bcg exposed patients late bcg relapses (beyond 24 months) likely benefit bcg . treatment decisions lg recurrences bcg (which considered category bcg failure) individualised according tumour characteristics. little known optimal treatment patients high-risk tumours could complete bcg instillations intolerance. 7.9.4. summary evidence - treatment failure intravesical therapy summary evidenceleprior intravesical chemotherapy impact effect bcg instillation.1atreatments rc must considered oncologically inferior patients bcg-unresponsive tumours.3 figure 7.2: treatment strategy recurrence intravesical bcgbcg = bacillus calmette-guérin; cis = carcinoma situ; hg = high-grade; ivu = intravenous urography;lg = low-grade; pdd = photodynamic diagnosis; turb = transurethral resection bladder.